C4 Therapeutics (CCCC) Accounts Payables (2019 - 2026)

C4 Therapeutics has reported Accounts Payables for 8 years, with the latest figure at $773000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 13.18% year-over-year to $773000.0; the trailing twelve-month figure through Mar 2026 stood at $773000.0 (up 13.18% YoY), and the FY2025 full-year result was $858000.0, down 35.39% from the prior year.
• Accounts Payables for Q1 2026 stood at $773000.0, down from $858000.0 in the prior quarter.
• The five-year high for Accounts Payables was $4.4 million in Q2 2022, with the low at $683000.0 in Q1 2025.
• Average Accounts Payables over 5 years is $1.7 million, with a median of $1.3 million recorded in 2025.
• Year-over-year, Accounts Payables sank 73.99% in 2022 and surged 142.72% in 2025.
• Tracing CCCC's Accounts Payables over 5 years: stood at $1.2 million in 2022, then rose by 23.38% to $1.4 million in 2023, then decreased by 8.16% to $1.3 million in 2024, then sank by 35.39% to $858000.0 in 2025, then dropped by 9.91% to $773000.0 in 2026.
• The last three Accounts Payables figures came in at $773000.0 (Q1 2026), $858000.0 (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.

Peer Comparison